The biosimilar regulatory pathway
Message to stakeholders to solve the issue of drug affordability in multiple myeloma
Clinical evidence supporting rituximab
Won Seog Kim
Novel agents in CLL: the importance of affordability
What is the best treatment in the next few years to achieve more treatment-free remission in CML?